Pembrolizumab Biosimilar(Dong-A ST)

帕博利珠单抗生物类似药（(Dong-A ST）

Report date: 2025/02/18 11:38:22

Base Information

Drug NamePembrolizumab Biosimilar(Dong-A ST)
Drug Alias NameDMB-3116
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionAnti-PD-1
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesDong-A ST Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDong-A ST Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A